Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Allergan Plc (AGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,307,868
  • Shares Outstanding, K 332,614
  • Annual Sales, $ 15,787 M
  • Annual Income, $ -5,096,400 K
  • 60-Month Beta 1.33
  • Price/Sales 3.16
  • Price/Cash Flow 4.05
  • Price/Book 0.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 3.54
  • Number of Estimates 17
  • High Estimate 3.65
  • Low Estimate 3.40
  • Prior Year 3.74
  • Growth Rate Est. (year over year) -5.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
135.50 +11.32%
on 02/22/19
152.86 -1.32%
on 03/18/19
+11.77 (+8.46%)
since 02/15/19
3-Month
125.84 +19.87%
on 12/26/18
161.03 -6.33%
on 01/24/19
+4.08 (+2.78%)
since 12/18/18
52-Week
125.84 +19.87%
on 12/26/18
197.00 -23.43%
on 10/03/18
-18.12 (-10.72%)
since 03/16/18

Most Recent Stories

More News
Medical Aesthetics Market is Determined to Reach US$ 21.0 Billion by 2024

New York, March 18, 2019: A few materials and devices are utilized as a part of the delivery of aesthetic treatments. Organizations that create or disperse restorative stylish devices are endeavoring to...

VRX.TO : 30.80 (-3.33%)
ZLTQ : 56.48 (unch)
AGN : 150.84 (-0.27%)
CYNO : 66.15 (+0.23%)
ELOS : 11.00 (unch)
NSRGF : 94.0700 (+0.34%)
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

JNJ : 137.17 (-0.31%)
MRK : 81.35 (-0.27%)
AGN : 150.84 (-0.27%)
RHHBY : 33.8600 (-0.21%)
PFE : 41.81 (+0.07%)
Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for AVYCAZ® (ceftazidime and avibactam), expanding...

AGN : 150.84 (-0.27%)
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.

MRK : 81.35 (-0.27%)
JNJ : 137.17 (-0.31%)
LLY : 125.24 (+1.05%)
AGN : 150.84 (-0.27%)
RHHBY : 33.8600 (-0.21%)
PFE : 41.81 (+0.07%)
BMY : 49.86 (-0.20%)
Allergan to Present New Data - "Extended Duration of Intraocular Pressure (IOP) Control with Intracameral Bimatoprost Sustained-Release (SR) Implant" -- Highlighting Clinical Advances at the American Glaucoma Society Annual Meeting

Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, will present new data including a late-breaking abstract for Bimatoprost SR at the Annual...

AGN : 150.84 (-0.27%)
Ocular Drug Delivery Technology Market Growing Demand and Trends 2019 to 2028

Ocular drug delivery technology is used in the treatment of ophthalmic diseases such as cataract, glaucoma, diabetic retinopathy etc. Manufactures are developing novel drug delivery technology which enables...

VRX.TO : 30.80 (-3.33%)
ALIM : 1.16 (-0.85%)
CLSD : 1.41 (-0.70%)
AGN : 150.84 (-0.27%)
NVS : 93.17 (-0.13%)
PFE : 41.81 (+0.07%)
OCUL : 4.06 (+0.25%)
Aesthetic Devices Market is Anticipated to Grow US$ 18.50 Billion by 2024

New York, March 13, 2019: Aesthetic devices are employed in rehabilitative and body sculpting surgeries majorly concentrating on increasing the quotient of mode. There are alternative edges to usage of...

VRX.TO : 30.80 (-3.33%)
ZBH : 125.32 (-0.48%)
ZLTQ : 56.48 (unch)
AGN : 150.84 (-0.27%)
CYNO : 66.15 (+0.23%)
ELOS : 11.00 (unch)
MMM : 208.49 (+0.20%)
SIEN : 9.22 (+4.30%)
NSRGF : 94.0700 (+0.34%)
US stock indexes end mostly higher, extending market's gains

TOKYO (AP) — Asian shares were lower Wednesday amid continuing global uncertainties that weighed on stocks as some traders took profits from a rally earlier in the week.

FITB : 28.76 (+1.55%)
AGN : 150.84 (-0.27%)
UNH : 255.00 (+1.43%)
BA : 372.28 (-1.77%)
Markets Right Now: Stocks end mostly higher; Boeing falls

NEW YORK (AP) — The latest on developments in financial markets (all times local):

FITB : 28.76 (+1.55%)
AGN : 150.84 (-0.27%)
UNH : 255.00 (+1.43%)
BA : 372.28 (-1.77%)
Allergan Announces FDA Acceptance of Migraine Candidate NDA

Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.

AGN : 150.84 (-0.27%)
LLY : 125.24 (+1.05%)
NVS : 93.17 (-0.13%)
TEVA : 16.64 (+0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade AGN with:

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Key Turning Points

2nd Resistance Point 153.73
1st Resistance Point 152.29
Last Price 150.84
1st Support Level 149.97
2nd Support Level 149.09

See More

52-Week High 197.00
Fibonacci 61.8% 169.82
Fibonacci 50% 161.42
Fibonacci 38.2% 153.02
Last Price 150.84
52-Week Low 125.84

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar